Novel PCSK9 Inhibitor Reduced LDL by 50%
Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.
Source: medscape.com
Eric Klug News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eric Klug. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eric Klug Today - Breaking & Trending Today
LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year
The novel agent has shown no immunogenicity issues thus far and might be a promising new PCSK9 inhibitor option.
Source: tctmd.com
Novel PCSK9 Inhibitor Cut LDL Cholesterol Levels by More Than Half
90% of high-risk patients on lerodalcibep achieved guideline-recommended cholesterol targets
Source: dicardiology.com
Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients
Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo.
Source: news-medical.net
Conference MDAngle: ACC 2024 Atherosclerosis and Lipid Management
Dr Erin D. Michos provides highlights from ACC 2024, including anticipated presentations, quick takeaways, and insights into how the presented research will impact patients.
Source: medscape.com